To evaluate the cost-effectiveness and healthcare value metrics, including quality-adjusted life years (QALYs) and net financial impact, of implementing Anemia inSights™ (AMT) in adult patients undergoing in-center hemodialysis in the U.S.
Key Findings:
AMT improved hemoglobin stability with a target attainment increase to 47%, indicating a significant improvement in patient management compared to no change in standard care.
Hemoglobin variability decreased by 45% in the AMT group versus 82% in standard care, highlighting the effectiveness of AMT in stabilizing hemoglobin levels.
Interpretation:
AMT demonstrates potential for improved anemia management in hemodialysis patients, leading to reduced hospitalization rates and overall healthcare costs through more effective dosing recommendations.
Limitations:
Cost-effectiveness analysis assumes zero costs for AMT to Medicare, which may not reflect real-world scenarios and could impact the generalizability of the findings.
Conclusion:
AMT is cost-effective and could lead to significant savings and improved patient outcomes in hemodialysis settings, addressing current challenges in anemia management.
